Committee Act (FACA) (Pub. L. 92–463), as amended, (5 U.S.C. App.), which sets forth standards for the formation and use of federal advisory committees.

Composition

The HITAC is comprised of at least 25 members, of which:

- No fewer than 2 members are advocates for patients or consumers of health information technology;
- 3 members are appointed by the HHS Secretary
 - 1 of whom shall be appointed to represent the Department of Health and Human Services and
 - 1 of whom shall be a public health official;
- 2 members are appointed by the majority leader of the Senate;
- 2 members are appointed by the minority leader of the Senate;
- 2 members are appointed by the Speaker of the House of Representatives;
- 2 members are appointed by the minority leader of the House of Representatives; and
- Other members are appointed by the Comptroller General of the United States.

Members will serve for one-, two-, or three-year terms. All members may be reappointed for a subsequent three-year term. Each member is limited to two three-year terms, not to exceed six years of service. After establishment, members shall be appointed for a three-year term. Members serve without pay, but will be provided per-diem and travel costs for committee services.

Recommendations

The HITAC recommendations to the National Coordinator are publicly available at https://www.healthit.gov/topic/federal-advisory-committees/recommendations-national-coordinator-health-it.

Public Meetings

The revised schedule of meetings to be held in 2020 is as follows:

- January 15, 2020 from approximately 9:30 a.m. to 2:30 p.m./Eastern Time at the Washington Plaza Hotel, 10 Thomas Circle NW, Washington, DC 20005
- February 19, 2020 from approximately 9:30 a.m. to 2:30 p.m./Eastern Time (virtual meeting)
- March 18, 2020 from approximately 9:30 a.m. to 2:30 p.m./Eastern Time (virtual meeting)
- March 26, 2020 from approximately 10:30 a.m. to 1:30 p.m./Eastern Time (virtual meeting)

- April 15, 2020 from approximately 9:30 a.m. to 2:30 p.m./Eastern Time (virtual meeting)
- May 20, 2020 from approximately 9:30 a.m. to 2:30 p.m./Eastern Time (virtual meeting)
- June 17, 2020 from approximately
 9:30 a.m. to 2:30 p.m./Eastern Time (virtual meeting)
- September date TBD
- October 21, 2020 from approximately 9:30 a.m. to 2:30 p.m./Eastern Time (virtual meeting)
- November 10, 2020 from approximately 9:30 a.m. to 2:30 p.m./ Eastern Time (virtual meeting)

All meetings are open to the public. Additional meetings may be scheduled as needed. For web conference instructions and the most up-to-date information, please visit the HITAC calendar on the ONC website, https://www.healthit.gov/topic/federal-advisory-committees/hitac-calendar.

Contact Person for Meetings: Lauren Richie, lauren.richie@hhs.gov. A notice in the Federal Register about last minute modifications that impact a previously announced advisory committee meeting cannot always be published quickly enough to provide timely notice. Please email Lauren Richie for the most current information about meetings.

Agenda: As outlined in the 21st Century Cures Act, the HITAC will develop and submit recommendations to the National Coordinator on the topics of interoperability, privacy and security, and patient access. In addition, the committee will also address any administrative matters and hear periodic reports from ONC. ONC intends to make background material available to the public no later than 24 hours prior to the meeting start time. If ONC is unable to post the background material on its website prior to the meeting, the material will be made publicly available at the location of the advisory committee meeting, and the background material will be posted on ONC's website after the meeting, at http://www.healthit.gov/hitac.

Procedure: Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee. Written submissions may be made to the contact person prior to the meeting date. An oral public comment period will be scheduled at each meeting. Time allotted for each presentation will be limited to three minutes. If the number of speakers requesting to comment is greater than can be reasonably accommodated during the scheduled public comment period, ONC will take written comments after the meeting.

Persons attending ONC's HITAC meetings are advised that the agency is not responsible for providing wireless access or access to electrical outlets.

ONC welcomes the attendance of the public at its HITAC meetings. Seating is limited at the location, and ONC will make every effort to accommodate persons with physical disabilities or special needs. If you require special accommodations due to a disability, please contact Lauren Richie at least seven (7) days in advance of the meeting.

Notice of these meetings are given under the Federal Advisory Committee Act (Pub. L. No. 92–463, 5 U.S.C., App. 2).

Dated: March 19, 2020.

Lauren Richie,

Office of Policy, Office of the National Coordinator for Health Information Technology.

[FR Doc. 2020–06345 Filed 3–25–20; 8:45 am]

BILLING CODE 4150-45-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Notice To Announce Request for Information on the Development of the National Institute of Diabetes and Digestive and Kidney Diseases Strategic Plan

AGENCY: National Institutes of Health, HHS.

ACTION: Request for Information.

SUMMARY: This Request for Information (RFI) is intended to gather broad public input to assist the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) in developing the NIDDK Strategic Plan. NIDDK invites input from: The scientific research community; patients and caregivers; health care providers and health advocacy organizations; scientific and professional organizations; federal agencies; and other stakeholders, including interested members of the public. Organizations are strongly encouraged to submit a single response that reflects the views of their organization and their membership as a whole.

DATES: Comments must be received by 11:59:59 p.m. (ET) on May 18, 2020 to ensure consideration.

ADDRESSES: All comments must be submitted electronically on the submission website, available at https://grants.nih.gov/grants/rfi/rfi.cfm?ID=106.

FOR FURTHER INFORMATION CONTACT: Please direct all inquiries to: Lisa

Gansheroff, NIDDKstrategicplan@nih.gov, 301.496.6623.

SUPPLEMENTARY INFORMATION: In accordance with the 21st Century Cures Act, NIH is required to regularly update their strategic plans. The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) is embarking on an Institute-wide strategic planning process. The goal of the process is to develop a broad vision for accelerating research into the causes, prevention, and treatment of diseases and conditions within the Institute's mission. This overarching trans-NIDDK Strategic Plan will complement NIDDK's disease-specific planning efforts. The strategic plan will have a 5year time horizon but will also include planning for longer term efforts that could be initiated within this time

A critical component of this strategic planning process is to seek input from the research and patient communities and others who have an interest in research within the mission of NIDDK. As part of that approach, the purpose of this Request for Information (RFI) is to invite input on opportunities and strategies to advance NIDDK's mission.

NIDDK will use responses collected as part of this RFI to inform the development of the Institute-wide Strategic Plan, which will be posted in draft form for additional public comment.

NIDDK conducts and supports biomedical research and research training and disseminates science-based information on: Diabetes and other endocrine and metabolic diseases; digestive diseases, including liver, gastrointestinal, and other diseases; nutritional disorders; obesity; and kidney, urologic, and hematologic diseases, to improve people's health and quality of life. Based on this mission, NIDDK has formulated the following broad themes for input, as a starting point for the planning process:

Themes for Input

- Advancing understanding of biological pathways and environmental contributors to health and disease.
- Advancing progress in pivotal clinical studies and trials for prevention, treatment, and cures in diverse populations.
- Advancing dissemination and implementation research on strategies to identify, adapt, scale-up, and integrate evidence-based interventions in diverse settings and populations.
- Promoting participant engagement—including patients and other participants as true partners in research.

- Advancing research training and career development to promote a talented, diverse biomedical research workforce.
- Promoting innovation, rigor and reproducibility in research, partnerships, communicating research results, and other critical efforts as part of efficient and effective stewardship of public resources.

NIDDK invites input from: The scientific research community; patients and caregivers; health care providers and health advocacy organizations; scientific and professional organizations; federal agencies; and other stakeholders, including interested members of the public.

NIDDK seeks input on any of the broad themes above. Your comments could include any of the following: Research opportunities for the themes highlighted above; innovative strategies to advance research progress; the challenges to progress in these areas; emerging trends, advances, technologies, analytic strategies, challenges in big data science, and perspectives that NIDDK should consider in this planning process; potential approaches to gauge research progress and success. Please also comment on any other topic that you find relevant to the development of the NIDDK Institute-wide Strategic Plan.

Organizations are strongly encouraged to submit a single response that reflects the views of their organization and membership as a whole.

Responses to this RFI are voluntary and may be submitted anonymously. Please do not include any information that you do not wish to make public. Proprietary, classified, confidential, or sensitive information should not be included in your response. The Government will use the information submitted in response to this RFI at its discretion. Individual feedback will not be provided to any responder. The Government reserves the right to use any submitted information on public websites, in reports, in summaries of the state of the science, in any possible resultant solicitation(s), grant(s), or cooperative agreement(s), or in the development of future funding opportunity announcements. This RFI is for informational and planning purposes only and is not a solicitation for applications or an obligation on the part of the Government to provide support for any ideas identified in response to it. Please note that the Government will not pay for the preparation of any information submitted or for use of that information.

NIDDK looks forward to your input and we hope that you will share this RFI with your colleagues.

Dated: March 20, 2020.

Bruce T. Roberts,

Health Science Policy Analyst, National Institute of Diabetes and Digestive and Kidney Diseases.

[FR Doc. 2020-06271 Filed 3-25-20; 8:45 am]

BILLING CODE 4140-01-P

DEPARTMENT OF HOMELAND SECURITY

U.S. Customs and Border Protection

Postponement of the April 2020 Customs Broker's License Examination

AGENCY: U.S. Customs and Border Protection, Department of Homeland Security.

ACTION: General notice.

SUMMARY: This document announces that U.S. Customs and Border Protection (CBP) has postponed the customs broker's license examination scheduled for April 1, 2020. The examination is postponed due to the unprecedented situation related to the coronavirus (COVID–19), which is having a nationwide impact on CBP's ability to conduct the examination.

DATES: The customs broker's license examination scheduled for April 1, 2020 is postponed.

FOR FURTHER INFORMATION CONTACT:

Randy Mitchell, Director, Commercial Operations, Revenue and Entry, Office of Trade, (202) 325–6532, or brokermanagement@cbp.dhs.gov.

SUPPLEMENTARY INFORMATION:

Background

Section 641 of the Tariff Act of 1930, as amended (19 U.S.C. 1641), provides that a person (an individual, corporation, association, or partnership) must hold a valid customs broker's license and permit in order to transact customs business on behalf of others, sets forth standards for the issuance of brokers' licenses and permits, and provides for the taking of disciplinary action against brokers that have engaged in specified types of infractions. This section also provides that an examination may be conducted to assess an applicant's qualifications for a license.

The regulations issued under the authority of section 641 are set forth in Title 19 of the Code of Federal Regulations, part 111 (19 CFR part 111). Part 111 sets forth the regulations